Our Company
INDEPENDENT MEDICAL EDUCATION PROGRAMS
The Alnylam grants office supports independent medical education activities provided to healthcare professionals (HCPs) to help close the professional practice gaps of learners and address their unmet educational needs. Activities should strive to ultimately improve patient care and must be compliant with all applicable legal and regulatory guidelines. Educational grants are considered financial awards for clinical, scientific, and disease state educational programs that provide meaningful education to healthcare professionals and researchers in areas of relevance to Alnylam, without tangible benefit to Alnylam in return.
As part of our ongoing commitment to putting patients first, Alnylam will accept grant requests for bona fide educational purposes from the following:
Educational providers that are accredited to provide continuing education (ie, CME, CE) by a national accrediting body, such as the Accreditation Council for Continuing Medical Education (ACCME), American Nurses Credentialing Center (ANCC), Accreditation Council for Pharmacy Education (ACPE), or other such accreditor. Alnylam will also support Independent Medical Education (IME) that is not designated for credit.
Educational providers can be any of the following types:
- Continuing education offices of academic medical centers, medical universities, hospitals, or community health centers
- Professional medical societies/associations
- Managed care organizations
- Medical education partner companies/providers
Requests for Proposals
Throughout the year, Alnylam will post Request for Proposals (RFP) to inform organizations and qualified medical education providers that we are interested in receiving requests for independent medical education activities pertinent to Alnylam’s areas of interest and aligned to specifications outlined in our RFPs.
The following are the available Request for Proposals:
ALNY-RFP-TTR-12 Transthyretin Amyloidosis (ATTR) – Clinical implementation of best practices to optimize patient care
2022 Transthyretin-mediated Amyloidosis (ATTR amyloidosis) Areas of Interest
- Increased awareness of ATTR amyloidosis, including distinction between hereditary and wild-type ATTR amyloidosis
- Improved clinical knowledge of the patient’s journey, disease burden, and identification of early symptoms
- Increased awareness of the multisystemic nature of the disease and the implications for multidisciplinary diagnosis and management
- Increased understanding of measurement and detection of disease progression
- Improved knowledge of genetic testing and counseling and implications for broader family
2022 Acute Hepatic Porphyria (AHP) Areas of Interest
- Increased awareness of the multisystemic nature of the disease and the implications for multidisciplinary diagnosis and management
- Improved knowledge of ordering and evaluating tests for diagnosis
- Increased knowledge of management of acute hepatic porphyria, including burden of disease and patient experience
2022 Primary Hyperoxaluria Type 1 (PH1) Areas of Interest
- Increased awareness of the diagnosis of PH1 and other rare kidney genetic kidney and kidney stone diseases
- Improved knowledge of the symptoms and laboratory tests associated with PH1
- Improved knowledge of nephrology genetic testing panels and their role in diagnosing genetic kidney disorders
- Improved knowledge of the link between genetic nephrology diagnoses and subsequent impact on clinical outcomes